Mauro  Ferrari net worth and biography

Mauro Ferrari Biography and Net Worth

Dr. Mauro Ferrari was appointed to the Arrowhead Board of Directors in 2010. Dr. Ferrari currently serves as Professor of Pharmaceutics at the University of Washington in Seattle, WA and CEO of DXT Pharmaceutics in Menlo Park, CA.

In the decade 2010-2019, he was President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), where he also served as Executive Vice President of Houston Methodist Hospital, and Senior Associate Dean of Weill Cornell Medical College in New York. He also served as President of the European Research Council. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University, and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. His previous academic appointments include tenured professorships at his graduate Alma Mater UC Berkeley, and The Ohio State University.

From 2003 to 2005, Dr. Ferrari served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute, where he led in the development of NCI’s program in Nanotechnology, which remains the largest program in NanoMedicine in the world. Dr. Ferrari has been serving as the Editor-in-Chief for “Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology” since 1997. We believe Dr. Ferrari’s qualifications to serve on the Board include his extensive training and experience in the fields of nanotechnology, biotechnology and biomedical applications. Dr. Ferrari has significant technical training in mathematics, engineering, medicine, and business, about 500 published articles, over 50 issued patents, and is the recipient of most prestigious academic awards in nanomedicine, the pharmaceutical sciences, and drug delivery technology. Additionally, Dr. Ferrari has extensive experience in developmental stage organizations having founded several startup companies.

What is Mauro Ferrari's net worth?

The estimated net worth of Mauro Ferrari is at least $579,467.41 as of October 9th, 2020. Dr. Ferrari owns 30,971 shares of Arrowhead Pharmaceuticals stock worth more than $579,467 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Ferrari may own. Learn More about Mauro Ferrari's net worth.

How do I contact Mauro Ferrari?

The corporate mailing address for Dr. Ferrari and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Mauro Ferrari's contact information.

Has Mauro Ferrari been buying or selling shares of Arrowhead Pharmaceuticals?

Mauro Ferrari has not been actively trading shares of Arrowhead Pharmaceuticals over the course of the past ninety days. Most recently, Mauro Ferrari sold 10,000 shares of the business's stock in a transaction on Friday, October 9th. The shares were sold at an average price of $48.00, for a transaction totalling $480,000.00. Following the completion of the sale, the director now directly owns 30,971 shares of the company's stock, valued at $1,486,608. Learn More on Mauro Ferrari's trading history.

Who are Arrowhead Pharmaceuticals' active insiders?

Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Arrowhead Pharmaceuticals?

In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 13 times. They sold a total of 227,632 shares worth more than $7,591,494.05. The most recent insider tranaction occured on July, 2nd when insider Tracie Oliver sold 9,394 shares worth more than $237,480.32. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.

Information on this page was last updated on 7/2/2024.

Mauro Ferrari Insider Trading History at Arrowhead Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/9/2020Sell10,000$48.00$480,000.0030,971View SEC Filing Icon  
6/26/2019Sell17,756$27.61$490,243.161,900View SEC Filing Icon  
10/28/2015Buy400$7.62$3,048.00View SEC Filing Icon  
10/9/2015Buy1,900$6.19$11,761.00View SEC Filing Icon  
See Full Table

Mauro Ferrari Buying and Selling Activity at Arrowhead Pharmaceuticals

This chart shows Mauro Ferrari's buying and selling at Arrowhead Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $18.71
Low: $18.04
High: $18.75

50 Day Range

MA: $19.96
Low: $17.70
High: $21.97

2 Week Range

Now: $18.71
Low: $17.05
High: $39.83

Volume

792,142 shs

Average Volume

1,199,403 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93